GSK3528869A+-ベピロビルセン市場：市場規模、予測、新たな洞察-2032年

GSK3228836（別名ベピロビルセン）は、GlaxoSmithKline（GSK）とIonis Pharmaの共同開発品です。ベピロビルセンは、B型肝炎ウイルスが感染した肝細胞（肝細胞）で自己複製し、免疫系によるクリアランスを回避して病気の慢性化を促進するウイルス抗原（タンパク質）を作るために使用するRNAを特異的に認識するように設計された、治験中のアンチセンスオリゴヌクレオチド（ASO）です。ベピロビルセンには、Toll様受容体8（TLR8）を介して免疫応答を刺激する特性もあり、免疫系が循環血液からウイルスを持続的に除去するのを助ける可能性があります。

GSK3528869Aは3成分の治療用ワクチンです。

今後数年間で、慢性B型肝炎の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、GSK3528869A+-ベピロビルセンの優位性に影響を与える可能性のある機会を模索しています。慢性B型肝炎に対する他の新興製品がGSK3528869A+-ベピロビルセンとの厳しい市場競争になると予想され、近い将来、後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国および中国における慢性B型肝炎治療薬のGSK3528869A+-ベピロビルセン市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 慢性B型肝炎におけるGSK3528869A+-ベピロビルセンの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 GSK3528869A+-ベピロビルセン市場評価

• 慢性B型肝炎におけるGSK3528869A+-ベピロビルセンの市場見通し
• 主要7ヶ国と中国の分析
  • 主要7ヶ国および中国における慢性B型肝炎治療薬GSK3528869A+-ベピロビルセンの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国
  • 中国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: GSK3528869A +- Bepirovirsen, Clinical Trial Description, 2023
• Table 2: GSK3528869A +- Bepirovirsen, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: GSK3528869A +- Bepirovirsen Market Size in the 7MM and China, in USD million (2019-2032)
• Table 6: GSK3528869A +- Bepirovirsen Market Size in the US, in USD million (2019-2032)
• Table 7: GSK3528869A +- Bepirovirsen Market Size in Germany, in USD million (2019-2032)
• Table 8: GSK3528869A +- Bepirovirsen Market Size in France, in USD million (2019-2032)
• Table 9: GSK3528869A +- Bepirovirsen Market Size in Italy, in USD million (2019-2032)
• Table 10: GSK3528869A +- Bepirovirsen Market Size in Spain, in USD million (2019-2032)
• Table 11: GSK3528869A +- Bepirovirsen Market Size in the UK, in USD million (2019-2032)
• Table 12: GSK3528869A +- Bepirovirsen Market Size in Japan, in USD million (2019-2032)
• Table 13: GSK3528869A +- Bepirovirsen Market Size in China, in USD million (2019-2032)

List of Figures

• Figure 1: GSK3528869A +- Bepirovirsen Market Size in the 7MM and China, USD million (2019-2032)
• Figure 2: GSK3528869A +- Bepirovirsen Market Size in the United States, USD million (2019-2032)
• Figure 3: GSK3528869A +- Bepirovirsen Market Size in Germany, USD million (2019-2032)
• Figure 4: GSK3528869A +- Bepirovirsen Market Size in France, USD million (2019-2032)
• Figure 5: GSK3528869A +- Bepirovirsen Market Size in Italy, USD million (2019-2032)
• Figure 6: GSK3528869A +- Bepirovirsen Market Size in Spain, USD million (2019-2032)
• Figure 7: GSK3528869A +- Bepirovirsen Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: GSK3528869A +- Bepirovirsen Market Size in Japan, USD million (2019-2032)
• Figure 9: GSK3528869A +- Bepirovirsen Market Size in China, USD million (2019-2032)

"GSK3528869A +- Bepirovirsen Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about GSK3528869A +- Bepirovirsen for chronic hepatitis B in the seven major markets and China. A detailed picture of the GSK3528869A +- Bepirovirsen for chronic hepatitis B in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China for the study period 2019 -2032 is provided in this report along with a detailed description of the GSK3528869A +- Bepirovirsen for chronic hepatitis B. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the GSK3528869A +- Bepirovirsen market forecast analysis for chronic hepatitis B in the 7MM and China, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic hepatitis B.

Drug Summary:

GSK3228836 (also known as bepirovirsen) is under the developmental process of the collaboration of GlaxoSmithKline (GSK) and Ionis Pharma. It is an investigational antisense oligonucleotide (ASO) designed to specifically recognize the RNA that the hepatitis B virus uses to replicate itself in the infected liver cells (hepatocytes) and make the viral antigens (proteins) that facilitate chronicity of the disease by helping to avoid clearance by the immune system. Bepirovirsen has the additional property of stimulating immune responses via Toll-like receptor 8 (TLR8), which may help the immune system to achieve durable clearance of the virus from circulating blood.

GSK3528869A is a three-component therapeutic vaccine:

• ChAd155-hIi-HBV: replication-defective simian (chimpanzee-derived) Group C adenovirus serotype 155 viral vector encoding sequences of two HBV protein antigens: the truncated hepatitis B core antigen (HBcAg) and the full-length small hepatitis B surface antigen (S-HBsAg)
• MVA-HBV: encoding the above two HBV protein antigens Modified vaccinia Ankara (MVA), which is a highly attenuated vaccinia virus strain
• HBc-HBs/AS01B-4: the above two HBV protein antigens enhanced by the AS01B-4 adjuvant, which is a liposomal combination of 3-O-desacyl-4'-monophosphoryl lipid A (MPL) from Salmonella minnesota and a saponin molecule (QS-21) from plant extract of Quillaja saponaria.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the GSK3528869A +- Bepirovirsen description, mechanism of action, dosage and administration, research and development activities in chronic hepatitis B.
• Elaborated details on GSK3528869A +- Bepirovirsen regulatory milestones and other development activities have been provided in this report.
• The report also highlights the GSK3528869A +- Bepirovirsen research and development activities in chronic hepatitis B across the United States, Europe, Japan, and China.
• The report also covers the patents information with expiry timeline around GSK3528869A +- Bepirovirsen.
• The report contains forecasted sales of GSK3528869A +- Bepirovirsen for chronic hepatitis B till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic hepatitis B.
• The report also features the SWOT analysis with analyst views for GSK3528869A +- Bepirovirsen in chronic hepatitis B.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

GSK3528869A +- Bepirovirsen Analytical Perspective by DelveInsight

• In-depth GSK3528869A +- Bepirovirsen Market Assessment

This report provides a detailed market assessment of GSK3528869A +- Bepirovirsen for chronic hepatitis B in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China. This segment of the report provides forecasted sales data from 2029 to 2032.

• GSK3528869A +- Bepirovirsen Clinical Assessment

The report provides the clinical trials information of GSK3528869A +- Bepirovirsen for chronic hepatitis B covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for chronic hepatitis B is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence GSK3528869A +- Bepirovirsen dominance.
• Other emerging products for chronic hepatitis B are expected to give tough market competition to GSK3528869A +- Bepirovirsen and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of GSK3528869A +- Bepirovirsen in chronic hepatitis B.
• Our in-depth analysis of the forecasted sales data of GSK3528869A +- Bepirovirsen from 2029 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the GSK3528869A +- Bepirovirsen in chronic hepatitis B.

Key Questions:

• What is the product type, route of administration and mechanism of action of GSK3528869A +- Bepirovirsen?
• What is the clinical trial status of the study related to GSK3528869A +- Bepirovirsen in chronic hepatitis B and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the GSK3528869A +- Bepirovirsen development?
• What are the key designations that have been granted to GSK3528869A +- Bepirovirsen for chronic hepatitis B?
• What is the forecasted market scenario of GSK3528869A +- Bepirovirsen for chronic hepatitis B?
• What are the forecasted sales of GSK3528869A +- Bepirovirsen in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China?
• What are the other emerging products available and how are these giving competition to GSK3528869A +- Bepirovirsen for chronic hepatitis B?
• Which are the late-stage emerging therapies under development for the treatment of chronic hepatitis B?

Table of Contents

1. Report Introduction

2. GSK3528869A +- Bepirovirsen Overview in Chronic hepatitis B

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. GSK3528869A +- Bepirovirsen Market Assessment

• 5.1. Market Outlook of GSK3528869A +- Bepirovirsen in Chronic hepatitis B
• 5.2. 7MM and China Analysis
  • 5.2.1. Market Size of GSK3528869A +- Bepirovirsen in the 7MM and China for Chronic hepatitis B
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of GSK3528869A +- Bepirovirsen in the United States for Chronic hepatitis B
  • 5.3.2. Market Size of GSK3528869A +- Bepirovirsen in Germany for Chronic hepatitis B
  • 5.3.3. Market Size of GSK3528869A +- Bepirovirsen in France for Chronic hepatitis B
  • 5.3.4. Market Size of GSK3528869A +- Bepirovirsen in Italy for Chronic hepatitis B
  • 5.3.5. Market Size of GSK3528869A +- Bepirovirsen in Spain for Chronic hepatitis B
  • 5.3.6. Market Size of GSK3528869A +- Bepirovirsen in the United Kingdom for Chronic hepatitis B
  • 5.3.7. Market Size of GSK3528869A +- Bepirovirsen in Japan for Chronic hepatitis B
  • 5.3.8. Market Size of GSK3528869A +- Bepirovirsen in China for Chronic hepatitis B

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options